SS-3150mg
SS-31 Canada — 50 mg, 100 mg Lyophilized Vials
Mitochondria-Targeted Peptide Research Compound
SS-31 is a mitochondria-targeted peptide studied in laboratory settings for its interaction with cellular energy systems and oxidative stress pathways. Research often focuses on its effects on mitochondrial efficiency, membrane stability, and overall cellular resilience in controlled experimental models.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
SS-31 is a synthetic tetrapeptide designed for controlled laboratory research involving mitochondrial-associated signaling systems. It is also known in scientific literature as elamipretide.
In research settings, SS-31 is studied in experimental models examining mitochondrial membrane interaction, bioenergetic signaling pathways, and oxidative stress–related regulatory frameworks under in vitro and preclinical conditions.
Third-party tested for purity, identity, quantity.
SS-31 is a mitochondria-targeted peptide evaluated in research focused on membrane-associated signaling and cellular bioenergetics. Experimental studies examine its interaction with mitochondrial membrane components and downstream signaling mechanisms within controlled laboratory environments.
Preclinical research publications have explored its role in mitochondrial function models and oxidative regulatory frameworks under structured experimental conditions.
SS-31 was developed during research efforts aimed at creating small peptides capable of selectively interacting with mitochondrial membranes. Investigations into mitochondrial-targeted peptide design led to the synthesis of compounds evaluated in bioenergetic and oxidative stress–related models.
Subsequent research documented its membrane interaction characteristics and signaling properties within experimental systems.
Laboratory investigations into SS-31 have focused on mitochondrial membrane interaction models and cellular bioenergetic signaling pathways. Research frameworks evaluate peptide interaction with cardiolipin-associated systems, oxidative stress regulation, and mitochondrial functional dynamics under controlled in vitro and preclinical conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Sabbah 2025, Najafi 2025, Heo 2025. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on bioenergetic. This heading marks where SS-31 is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Najafi 2025. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on cardiolipin or associated. This heading marks where SS-31 is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 4 primary papers published in 2025 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for SS-31, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
SS-31 is also referred to as elamipretide, MTP-131.
SS-31 is commonly described online in connection with more energy, better mitochondrial function and slower ageing. In the research literature the same compound is filed under mitochondrial membrane interaction models, bioenergetic signaling pathway research and oxidative stress regulatory framework studies.
The 4 papers cited on this page, published between 2025 and 2025 (2 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for SS-31 is per lot, not per product. Across the strengths currently stocked: 50mg lot SS31-CA-26F-50 returned 99.768% purity, 50.86 mg measured, 101.7% of the labelled 50 mg; 100mg lot SS31-CA-26I-100 returned 99.778% purity, 96.1 mg measured, 96.1% of the labelled 100 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is SS-31; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for SS-31, across the strengths stocked they run from 96.1% to 101.7% of label. Where a lot comes in under 100% that is published too: 100mg at 96.1%. A supplier who only publishes flattering numbers has not told you anything.
Each strength of SS-31 carries its own lot code and its own certificate — SS31-CA-26F-50, SS31-CA-26I-100 are separate tests, not one result applied across the range. The code printed on the vial you receive is the one to match, and matching it is what ties the material in hand to a test that was actually run on it.
Researchers who buy SS-31 in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
SS-31 is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 4 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 50mg of lyophilized SS-31. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Contemporary insights into elamipretide’s mitochondrial mechanism of action and therapeutic effects.
PubMedElamipretide enhances post-thaw rooster sperm quality by mitigating oxidative stress and optimizing mitochondrial function during cryopreservation.
PubMedAcute mitochondrial reactive oxygen species emissions drive mitochondrial dysfunction after traumatic muscle injury in male mice.
PubMedSS-31: A promising therapeutic agent against bleomycin-induced pulmonary fibrosis in mice.
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Out of stockPeptides
Long-Acting Amylin Analogue · 5 & 10 mg Cagrilintide is a synthetic peptide developed for controlled laboratory research involving amylin receptor signaling systems. It is structurally designed to interact with amylin-associated pathways within experimental environments.
CAG-CA-26A-0199.446%
5.62 mg / 5 mg
$69.95CAD
